Morgan Stanley analyst David Lewis maintained a Sell rating on Grifols SA (GRFS) today and set a price target of $19. The company’s shares opened today at $18.12, close to its 52-week low of $17.42.
According to TipRanks.com, Lewis is a 5-star analyst with an average return of 10.9% and a 65.3% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Baxter International, and Edwards Lifesciences.
Currently, the analyst consensus on Grifols SA is a Moderate Sell with an average price target of $19.
See today’s analyst top recommended stocks >>
Based on Grifols SA’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $174 million. In comparison, last year the company had a net profit of $274 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Grifols SA is a vertically integrated global producer of plasma derivatives. Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers. The company operates through the following segments: Bioscience, Hospital, Diagnostic and Raw Materials.
